Zacks Research Weighs in on Stryker's Q1 Earnings (NYSE:SYK)

Stryker Co. (NYSE:SYK - Free Report) - Investment analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for shares of Stryker in a research note issued on Monday, November 18th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical technology company will earn $2.82 per share for the quarter, up from their prior forecast of $2.74. The consensus estimate for Stryker's current full-year earnings is $12.06 per share. Zacks Research also issued estimates for Stryker's Q3 2025 earnings at $3.26 EPS, Q4 2025 earnings at $4.23 EPS and FY2025 earnings at $13.53 EPS.

Several other analysts have also recently weighed in on SYK. JPMorgan Chase & Co. raised their price target on Stryker from $375.00 to $420.00 and gave the company an "overweight" rating in a report on Wednesday, October 30th. Truist Financial increased their price objective on Stryker from $370.00 to $380.00 and gave the company a "hold" rating in a research report on Wednesday, October 30th. Piper Sandler reiterated an "overweight" rating and set a $420.00 price objective (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Wells Fargo & Company increased their price objective on Stryker from $381.00 to $405.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. Finally, Barclays increased their price objective on Stryker from $402.00 to $418.00 and gave the company an "overweight" rating in a research report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and a consensus price target of $393.65.

Stryker Stock Performance

Shares of SYK opened at $385.68 on Thursday. The stock's 50-day simple moving average is $365.46 and its 200 day simple moving average is $348.66. The stock has a market capitalization of $147.03 billion, a price-to-earnings ratio of 41.34, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker has a 52-week low of $285.79 and a 52-week high of $398.20.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion for the quarter, compared to analysts' expectations of $5.37 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. The business's revenue for the quarter was up 11.9% compared to the same quarter last year.

Insider Activity

In other Stryker news, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction on Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the completion of the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,715,540. The trade was a 17.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company's stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 67,381 shares of company stock worth $24,825,275 in the last quarter. 5.90% of the stock is owned by company insiders.

Institutional Trading of Stryker

A number of institutional investors and hedge funds have recently modified their holdings of the business. Avestar Capital LLC increased its holdings in shares of Stryker by 1.1% in the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company's stock worth $1,065,000 after purchasing an additional 31 shares in the last quarter. Patrick M Sweeney & Associates Inc. increased its holdings in shares of Stryker by 1.5% in the 3rd quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company's stock worth $793,000 after purchasing an additional 32 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of Stryker by 4.0% in the second quarter. Versant Capital Management Inc now owns 864 shares of the medical technology company's stock worth $294,000 after acquiring an additional 33 shares during the period. Stanley Laman Group Ltd. grew its holdings in shares of Stryker by 4.6% in the second quarter. Stanley Laman Group Ltd. now owns 752 shares of the medical technology company's stock worth $256,000 after acquiring an additional 33 shares during the period. Finally, Plimoth Trust Co. LLC grew its holdings in shares of Stryker by 0.3% in the second quarter. Plimoth Trust Co. LLC now owns 9,476 shares of the medical technology company's stock worth $3,224,000 after acquiring an additional 33 shares during the period. Institutional investors own 77.09% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.